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Abstract
Background: Transplant patients would benefit from reduction of immunosuppression providing that graft rejection is
prevented. We have evaluated a number of immunological markers in blood of patients in whom tacrolimus was withdrawn
after renal transplantation. The alloreactive precursor frequency of CD4+ and CD8+ T cells, the frequency of T cell subsets
and the functional capacity of CD4+CD25+FoxP3+ regulatory T cells (Treg) were analyzed before transplantation and before
tacrolimus reduction. In a case-control design, the results were compared between patients with (n=15) and without
(n=28) acute rejection after tacrolimus withdrawal.
Principal Findings: Prior to tacrolimus reduction, the ratio between memory CD8+ T cells and Treg was higher in rejectors
compared to non-rejectors. Rejectors also had a higher ratio between memory CD4+ T cells and Treg, and ratios ,20 were
only observed in non-rejectors. Between the time of transplantation and the start of tacrolimus withdrawal, an increase in
naive T cell frequencies and a reciprocal decrease of effector T cell percentages was observed in rejectors. The proportion of
Treg within the CD4+ T cells decreased after transplantation, but anti-donor regulatory capacity of Treg remained unaltered
in rejectors and non-rejectors.
Conclusions: Immunological monitoring revealed an association between acute rejection following the withdrawal of
tacrolimus and 1) the ratio of memory T cells and Treg prior to the start of tacrolimus reduction, and 2) changes in the
distribution of naive, effector and memory T cells over time. Combination of these two biomarkers allowed highly specific
identification of patients in whom immunosuppression could be safely reduced.
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Introduction
Currently, 1-year graft survival rates after renal transplantation
are exceeding 90%. However, the life-long administration of
immunosuppressive drugs is accompanied by many side effects.
Next to increased risk of infections and malignancies, the use of the
calcineurin inhibitors (CNI) cyclosporine and tacrolimus is
associated with nephrotoxicity, which can contribute to long-term
graft failure [1,2]. Withdrawal of CNI, once stable graft function is
achieved, has therefore been attempted in several studies but was
associated with an increased risk for acute rejection [3,4]. On the
other hand, successful discontinuation of CNI results in improved
renal function and blood pressure, and long-term follow up of
patients after CNI withdrawal has shown a favorable outcome
[5,6]. Thus, it is highly desirable to identify transplant patients in
whom CNI withdrawal can be successful. To this end, there is a
need for in vitro monitoring tools.
CD4+ and CD8+ effector T cells play a central role in the
pathogenesis of allograft rejection [7]. CD4+CD25+FoxP3+
regulatory T cells (Treg) are involved in maintaining tolerance
towards self antigens, and they can regulate alloreactivity as well
[8,9]. The quantification of alloreactivity, in terms of balance
between effector cells and Treg, may allow the identification of
patients at risk for acute rejection. Early attempts to characterize
alloreactivity have focused on the functional capacity of allor-
eactive T cells in mixed lymphocyte reactions (MLR), but these
assays showed little predictive value in transplantation [10]. Better
information was provided by MLR-based limiting dilution assays,
estimating the precursor frequencies of cytotoxic T lymphocytes
(CTLp) and helper T cells (HTLp) [11]. In bone marrow
transplantation, high CTLp frequencies were associated with
prolonged leukemia free survival time [12]. However, the benefit
of CTLp assessment in solid organ transplantation remains
controversial [13,14]. Using Elispot assays, low numbers of
donor-specific IFN-c producing T cells were associated with
stable long-term renal function [15,16]. Moreover, a high pre-
transplant reactivity to a panel of allogeneic stimulator cells was
correlated with an increased risk for acute rejection after renal
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2711transplantation [17]. Protein profiling of serum to predict rejection
has shown promising results in experimental models, but these
data have to be confirmed in clinical studies [18].
To date, studies on the role of Treg in alloreactivity are limited
due to the low number of Treg in the circulation. The indirect
assessment of Treg function in depletion assays, showed that Treg
are able to regulate anti-donor responses after transplantation
[19,20], but firm evidence for their role in protection against
rejection remains to be provided.
In this study, the level of immunosuppression was reduced to a
CNI free regimen in renal transplant patients with stable graft
function, according to a standard protocol. Blood samples were
collected before transplantation and before the start of tacrolimus
withdrawal. Using a case-control design, we compared the T cell
subset distribution and ex vivo T cell responses between patients
who experienced an acute rejection period following the reduction
of immunosuppression and patients in whom immunosuppression
was reduced successfully.
Methods
Transplant patients and immunosuppression
Patients received a renal allograft in our hospital between
January 2003 and December 2004. Immunosuppression consisted
of tacrolimus in combination with mycophenolate mofetil (MMF)
and prednisolone. Patients received 100 mg of prednisolone
intravenously during the first 3 days after transplantation and
subsequently an oral dose of 15–25 mg/day, tapered to a
maintenance dose of 0.1 mg/kg/day. Tacrolimus was started at
day 1 or 2 after transplantation at 0.15 mg/kg/day and the dose
was subsequently adjusted to achieve whole-blood trough
concentrations of 15–20 ng/mL during days 0–14, 10–15 ng/
mL during weeks 3–6, and 5–10 ng/mL from week 7. Whole
blood tacrolimus concentrations were measured by the IMx
analyzer (Abbott Laboratories, Abbott Park, IL, USA). MMF was
administered at 1000 mg twice daily with a dose reduction to
750 mg twice daily at 2 weeks after transplantation. Induction
therapy with polyclonal or monoclonal antibodies was not used.
At 4 months after transplantation, patients were selected for
reduction of their immunosuppression (including withdrawal of
tacrolimus) when they met the following inclusion criteria: stable
graft function, and at least 1 HLA-B and 1 HLA-DR match
between donor and recipient. Patients who received a kidney from
a HLA-identical living donor, patients with two or more previously
failed grafts, patients with PRA .85%, non-Caucasian patients,
and patients that had experienced a steroid-resistant acute
rejection episode after their current transplantation were excluded.
In addition, patients with severe osteoporosis and patients with
bone marrow depression were not included. At first instance,
MMF was substituted for azathioprine (Aza, 3 mg/kg daily). The
dose of Aza was adjusted in case of leukocytopenia or elevated
liver enzymes. When patients did not tolerate a minimum Aza
dose of 2 mg/kg/day, MMF was reintroduced. Two months later,
six months after transplantation, the tacrolimus dose was gradually
reduced to zero over a period of 4 weeks. Meanwhile, the
prednisolone dose was increased to 0.15 mg/kg/day. The
resulting immunosuppressive therapy after conversion consisted
of azathioprine (at least 2 mg/kg/day; otherwise MMF 750 mg
twice daily) and prednisolone (0.15 mg/kg/day). All patients were
evaluated for acute rejection episodes during the first 6 months
after withdrawal of tacrolimus. When there was a deterioration of
graft function without clear prerenal or postrenal cause, a graft
biopsy was taken. Protocol biopsies at fixed time points were not
performed. The study was approved by the Intstitutional Review
Board of the Radboud University Nijmegen Medical Centre. All
participants gave written informed consent.
Cell isolation and culture conditions
Blood samples (20 ml) were collected before transplantation
(T0) and prior to tacrolimus withdrawal (T1). Donor cells were
obtained from peripheral blood (living donors) or spleen tissue
(deceased donors). For 3
rd party controls, buffy coats were
obtained from healthy blood donors (Sanquin Blood Bank region
South East, Nijmegen, the Netherlands). Cell isolation and culture
were conducted as described elsewhere [21]. All cells from donors
and recipients were frozen prior to use in analyses. HLA typing
was conducted according to ASHI standards.
Expression of cell surface markers and of FoxP3
PBMC (1*10
5) were labeled with fluorochrome-conjugated
monoclonal antibodies in PBS-BSA buffer for 209 at room
temperature (RT) in the dark. Samples were measured on a
Coulter Epics XL flowcytometer (Beckman Coulter, Fullerton,
CA) and analyzed using Coulter Epics Expo 32 software. The
following antibodies were used: anti-CD8-FITC (DK25), anti-
CD27-FITC (M-T271), anti-CD45RO-FITC (UCHL1), anti-
CD25-PE (M-A251), anti-CD28-PE (CD28.1), anti-CD45RA-PE
(HI100), anti-CD3-ECD (UCHT1), anti-CD62L-ECD
(DREG56), anti-CD8-PC5 (B9.11), and anti-CD4-PC5 (13B8.2).
FoxP3-FITC (PCH101) staining was performed according to the
manufacturer’s procedures (eBioscience, San Diego, CA, USA).
Appropriate isotype control mAbs were used for marker settings.
CFSE-based MLR
The number of donor- and 3
rd party-reactive CD4+ and CD8+
T cells was determined using a CFSE-based mixed lymphocyte
reaction (CFSE-MLR) [22,23]. Patient PBMC (10*10
6) were
labeled with 1 mM CFSE (Molecular Probe, Eugene, OR, USA) in
CFSE labeling buffer (PBS containing 0.02% HPS) for 10 minutes
at RT in the dark and the labeled cells (1*10
5) were stimulated
with irradiated (30 Gy) PKH (Sigma-Aldrich, St Louis, USA)
labeled donor cells (1*10
5) in 96-wells round bottom plates. As
controls, patient PBMC were cultured with either PKH labeled
irradiated pooled 3
rd party PBMC, cultured alone (negative
control), or cultured in the presence of anti-CD3/antiCD28
expander beads (positive control). At day 6, the cells were stained
for CD4 and CD8.
Expansion and functional analysis of CD4+CD25
high
regulatory T cells
Patient PBMC (5–10*10
6) were incubated with CD4-FITC
(clone MT310, Dako, Glostrup, Denmark) and CD25-PE (clone
M-A251, BD Bioscience, USA) for 20 minutes at RT in the dark.
CD4
+CD25
high and CD4
+CD25
neg control cells were separated
using high purity fluorescence activated cell sorting (FACS, Altra
flowcytometer, Beckman Coulter, USA). Sorted CD4
+CD25
high
and CD4
+CD25
neg T cells were expanded as described previously
[21]. To analyze their suppressive potential, a primary MLC was
set up, consisting of 4
th party responder PBMC and donor or 3
rd
party stimulator cells. Fourth party responder PBMC were used
instead of patient PBMC because of the low proliferative response
of the patient PBMC to donor stimulator cells (likely due to close
HLA matching), which hampered the read-out of the putative
suppression by Treg. The expanded CD4+CD25
high and
CD4+CD25
neg (control) cells were added at increasing ratios to
this MLC. It was expected that in the MLC with donor stimulator
cells (and not 3
rd party stimulator cells), the added donor-specific
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th
party responders by means of linked suppression. Proliferation was
measured by
3H incorporation.
Statistical analysis
Patients who experienced an acute rejection after tacrolimus
withdrawal and a control group of non-rejecting patients, were as
closely as possible matched for the followingitems: age of donor and
recipient (,50 versus $50), total number of HLA-mismatches,
percentage PRA (,5%, $5%), and first or re-transplantation. Data
obtained from flow cytometry and CFSE-MLR analyses were
compared between the two groups using a Mann-Whitney U-test.
For analysis of changes in time within patients a Wilcoxon signed
rank test was used. Correlation between values of different time
points was analyzed with Spearman’s rank test. A p-value #0.05
was considered statistically significant.
Results
Patient characteristics
Sixty-six patients fulfilled the inclusion criteria and were treated
according to the protocol. Twenty-four patients (36%) experienced
an acute rejection following the withdrawal of tacrolimus. In 22/
24 patients the rejections were confirmed by histology according to
the 2001 revised Banff classification [24]. In two patients, the
clinical picture and response to therapy was compatible with acute
rejection, but no graft biopsy was performed for logistical reasons.
All acute rejection episodes were treatable and none of the patients
lost their graft within the follow-up period of six months after
tacrolimus withdrawal.
In 15 cases with acute rejection sufficient material from donors
as well as recipients was available to perform the analyses
described below. For each case, we selected two controls from
the group of non-rejectors (n=42), based on optimal matching for
a set of relevant parameters (as described in materials and methods
section). Because sufficient material was not available for all
donors and recipients, the ultimate number of controls was 28.
Except for a difference in the degree of HLA-DR matching, the
clinical characteristics did not differ significantly between rejectors
and non-rejectors (Table 1).
Frequencies of effector, memory and regulatory T cell
subsets
T cell subset distribution was analyzed in blood samples collected
immediately before the start of tacrolimus dose reduction (T1).
Using antibodies directed against CD62L and isoforms of CD45,
naive (TN, CD45RA+CD62L+), effector (TE, CD45RA+CD62L-),
effector memory (TEM, CD45RO+CD62L-) and central memory
(TCM, CD45RO+CD62L+) T cell subsets were identified [25,26].
Neither in the CD4+ T cell pool, nor in the CD8+ T cell
compartment did the distribution of the four subsets differ between
rejectors and non-rejectors (Figure 1). A similar discrimination
between naı ¨ve, effector and memory T cells was made on the basis
of CD27 and CD28 expression which neither revealed significant
differences between rejectors and non-rejectors (data not shown).
Immediately prior to the start of tacrolimus dose reduction, the
median frequency of Treg was 1.6% and 2.0% of the total CD4+
T cell subset for rejectors and non-rejectors, respectively (NS;
Figure 1E).
Nextto the sizeof the T cell subsets, the balance between reactive
andregulatoryT cellsmightbeanimportantdeterminant ofthe risk
of rejection [27–29]. Interestingly, the ratio between the percentage
of CD8+ memory T cells (TEM and TCM combined) and the
percentage of Treg was significantly higher in rejectors compared
with non-rejectors (p=0.007). A similar difference was observed in
the CD4+ T cell compartment (p=0.032), where low ratios (,20)
were only observed for non-rejectors (Figure 1F). Since the group of
non-rejectors contained 8 patients without DR mismatches, while
none of the rejectors were fully DR matched, we repeated the
analysis after the exclusion of DR matched transplantations. Again,
the ratio between CD8+ memory T cells and Treg as well as the
ratio between CD4+ memory T cells and Treg were higher in
rejectors (p=0.004 and p=0.01, respectively). To get informed
about the reproducibility of this parameter, we also measured the
ratio between memory T cells and Treg in blood samples taken two
months prior to the start of tacrolimus withdrawal, and compared
these values with those obtained immediately before the tacrolimus
dose reduction. For the ratio between CD8+ memory T cells and
Treg the values did not differ significantly between both time points
and the correlation coefficient was 0.89 (P,0.001). For the ratio
between CD4+ memory T cells and Treg the values of both time
points did not differ either, and the correlation coefficient was 0.74
(P,0.001). We therefore conclude that the variability in time of this
parameter is limited.
CD4+ and CD8+ alloreactive T cell precursor frequency
and mitotic activity
The precursor frequencies of donor reactive CD4+ and CD8+
T cells ranged from 0.1–6.8%, increasing with the number of HLA
mismatches, and did not differ between rejectors and non-rejectors
(Figure 2B). Differences were neither observed in the precursor
frequencies of 3
rd party-reactive CD4+ or CD8+ T cells
(Figure 2C).
The number of mitotic events was higher in third party
alloreactive T cells as compared to donor reactive CD4+ and
CD8+ T cells, but did not differ between rejectors and non-
rejectors (Figures 2D and 2E).
Suppressive potential of Treg
The suppressive capacity of peripheral blood Treg was studied in
9 patients (5 rejectors and 4 non-rejectors). CD4+CD25
high were
isolated from PBMC. To obtain sufficient cell numbers for
functional analysis, the cells were expanded using a previously
Table 1. Patient characteristics.
Rejectors
(n=15)
Non-rejectors
(n=28) p-value
Gender (male/female) 9/6 18/10 0.78
Patient age (years) 43615 40613 0.65
Donor age (years) 49614 49610 0.89
Donor living/deceased 6/9 8/20 0.45
HLA mismatches (0/$1)
HLA-A 5/10 15/13 0.21
HLA-B 4/11 9/19 0.71
HLA-DR 0/15 8/20 0.02
Cold ischemia time (hours)* 20681 7 65 0.30
PRA pretransplant ($5%) 1 6 0.19
Retransplantation 0 6 0.05
Acute rejection prior to inclusion 1 0 0.17
Azathioprine/MMF at start of
tacrolimus withdrawal
11/4 19/9 0.71
*deceased donors only
doi:10.1371/journal.pone.0002711.t001
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PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2711Figure 1. The frequency of effector, memory and regulatory T cell subsets in the peripheral blood of renal transplant patients
immediately before the start of tacrolimus dose reduction (T1). (A) Representative dot plots of CD62L versus CD45RA and CD62L versus
CD45RO. The analysis was performed on cells within the lymphocyte gate in the forward/side scatter plot. (B) The percentage of naı ¨ve (TN,
CD45RA+CD62L+), effector (TE, CD45RA+CD62L-), central memory (TCM, CD45RO+CD62L+) and effector memory (TEM, CD45RO+CD62L-) T cells within
the total CD4+ T cell subset. R vs. NR=not significant. (C) As described under A, for CD8+ T cells. R vs. NR=not significant. (D) Representative dot plot
of CD25 versus FoxP3 in CD4+ lymphocytes. (E) The percentage of CD25+FoxP3+ regulatory T cells (Treg) within CD4+ lymphocytes. R vs. NR=not
significant. (F) The ratio between the percentage of memory T cells and the percentage of Treg.
doi:10.1371/journal.pone.0002711.g001
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showed potent abilityto suppressboth anti-donor and anti-3
rd-party
responses. Considerable variation was observed in the suppressive
potential of Treg between individual patients, but overall no
differences were observed between rejectors and non-rejectors
(Figure 3). The expanded CD4+CD25- control T cells did not
reveal suppressive capacity in any of the patients (data not shown).
Changes in the distribution of effector and memory T cell
subsets over time
Having established a difference in the ratio between memory
and Treg before the reduction of tacrolimus (T1), we wondered
whether changes over time would provide additional information.
Analysis of the immunological markers before transplantation
(T0), showed no differences between rejectors and non-rejectors.
Figure 2. The functional capacity of allo- and 3
rd party-reactive CD4+ and CD8+ T cells and CD4+CD25
high regulatory T cells isolated
from the peripheral blood of transplant patients immediately before the start of tacrolimus dose reduction (T1). A CFSE-MLR was
used to determine the precursor frequency and mitotic events of alloreactive CD4+ (left) and CD8+ (right) T cells. CFSE labeled patient PBMC (1*10
5)
were stimulated with PKH labeled donor or 3
rd party cells (1*10
5) for 6 days. Using flow cytometry, patient T cells were gated based on forward/side
scatter and PKH exclusion and subsequent CD4 and CD8 staining. An example is shown in (A). The precursor frequency and mitotic events of
alloreactive CD4+ and CD8+ T cells were calculated on the basis of the CFSE dilution pattern using Modfit LT
TM software [22]. (B) The precursor
frequency of donor reactive CD4+ and CD8+ T cells. (C) The precursor frequency of 3
rd party reactive CD4+ and CD8+ T cells. (D) The number of
mitotic events of alloreactive CD4+ and CD8+ T cells. (E) The number of mitotic events of 3
rd party reactive T cells. R vs. NR=not significant.
doi:10.1371/journal.pone.0002711.g002
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relative increase between T0 and T1 in the percentage of naive T
cells and all but one showed a decrease in the percentage of
effector T cells, while in non-rejectors the pattern of changes was
diverse (Figure 4A). In the CD8+ T cell compartment, there were
comparable shifts in T cell subset percentages, but less outspoken
than in the CD4+ T cell population (Figure 4B).
For both rejectors and non-rejectors, the median percentage of
Treg within the CD4+ T cells was lower prior to tacrolimus
reduction (1.6% and 2.0%, respectively) compared to pretrans-
plant values (2.6% and 2.9%, respectively, p,0.01) (Figure 4C).
Taken together, a decrease in the percentage of naı ¨ve T cell
levels identified transplant patients at low risk for acute rejection
following reduction of immunosuppression.
Changes in the functional capacity of CD4+ and CD8+ T
cells over time
The precursor frequency and mitotic events of donor and 3
rd
party reactive CD4+ and CD8+ T cells showed little variation over
time and the changes did not differ between rejectors and non-
rejectors (Figures 5A and 5B). In addition, the ability of isolated
Treg to suppress alloreactivity was comparable at the time of
transplantation and the start of tacrolimus withdrawal (Figure 5C).
Predictive value of immunological markers for the
occurrence or freedom of rejection
As stated above, two markers were associated with successful
reduction of immunosuppression: 1) a low ratio (,20) of memory
CD4+ T cells: Treg prior to the start of immunosuppression
reduction, and 2) a decrease in the percentage of naive T cells
before start of tacrolimus reduction compared to pre-transplant
values. Combination of these two markers resulted in a test with a
high predictive value. We defined a positive test result (associated
with rejection) as the absence of both markers, and a negative test
result (associated with absence of rejection) as the presence of one
or both markers. Both markers were available in 33 patients (12
rejectors and 21 non-rejectors). The sensitivity of the test for
detecting a subsequent rejection was 100% (12/12) while the
specificity was 76% (16/21). The positive predictive value (markers
absent=positive test) with respect to subsequent rejection was
76% (12/17), while the negative predictive value (one or both
markers present=negative test) was 100% (16/16). In conclusion,
the combination of the two biomarkers was very useful to identify
patients in whom the immunosuppressive therapy could be safely
reduced.
Discussion
In this case-control study, we have evaluated a number of T cell
markers to predict the occurrence of acute renal allograft rejection
following the discontinuation of tacrolimus. We did not aim to
study the kinetics of T cell populations during rejection and after
treatment thereof. Rather, we tried to identify markers of a state of
allograft acceptance that may allow minimization of immunosup-
pression. In samples taken immediately before the withdrawal of
tacrolimus, the ratio between memory CD8+ or memory CD4+ T
cells and Treg was significantly higher in patients who experienced
a rejection episode compared to non-rejectors. Apparently, an
enhanced memory T cell: Treg ratio did not result in rejection as
long as sufficient immunosuppression was provided. Reduction of
immunosuppression tipped the balance towards rejection in a
number of these patients. Our findings underscore the importance
of a balance between effector/memory and regulatory mecha-
nisms in the maintenance of immune homeostasis as has been
demonstrated in several studies [27–29].
In addition, we observed that the change in T cell subset
distribution between transplantation and the initiation of tacroli-
mus withdrawal was different between rejectors and non-rejectors.
In the group of rejectors, an increase over time was observed in the
percentage of naive T cells in the peripheral blood, with a
reciprocal decrease in the percentage of effector T cells. Although
more pronounced for CD4+ T cells, this phenomenon was also
observed for CD8+ T cells. Without the analysis of other immune
compartments and graft tissue, it is difficult to interpret these
intriguing findings.
Figure 3. The suppressive potential of Treg isolated from transplant patients immediately before the start of tacrolimus dose
reduction. R=rejectors (n=5), NR=non-rejectors (n=4). CD4+CD25
high and CD4+CD25
2 control cells were isolated from patient PBMC using
fluorescence activated cell sorting resulting in .95 purity. The cells were expanded using anti-CD3/CD28 coated expander beads in combination with
IL-2 and IL-15 for 14–21 days. After expansion, Treg were rested for 2–3 days after which their capacity to suppress anti-donor and anti-3
rd party
responses was evaluated in a suppression assay, in which Treg were added at increasing ratios to a newly setup MLR (with donor or 3
rd party
stimulator cells). Proliferation was measured at day 6 using
3H incorporation The percentage inhibition of proliferation (y-axis) of anti-donor (left) or
anti-3
rd-party (right) responses by Treg, added at increasing ratios (x-axis) to the MLR, isolated from rejectors and non-rejectors. R vs. NR=not
significant.
doi:10.1371/journal.pone.0002711.g003
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changes in T cell subsets over time, resulted in a test, that is highly
sensitive in the detection of patients that will develop a rejection
after the withdrawal of tacrolimus at six months after renal
transplantation. Accordingly, when confirmed in another study,
this test could be very useful to identify renal transplant patients in
whom immunosuppression can be safely reduced.
Until now, in vitro monitoring tools in solid organ transplan-
tation have mostly been used to predict the course early after
transplantation, and the most relevant information has been
Figure 4. Changes in the frequency of naı ¨ve, effector, memory and regulatory T cell subsets in the peripheral blood of transplant
patients between the time of transplantation (T0) and the start of tacrolimus withdrawal (T1). A positive value indicates an increase and
a negativevalueindicates a decrease of the valuein time. The change in thepercentage of naı ¨ve (TN, CD45RA+CD62L+), effector (TE, CD45RA+CD62L-),
central memory (TCM, CD45RO+CD62L+) and effector memory (TEM, CD45RO+CD62L-) T cell subsets within (A) the total CD4+ T cell population, and (B)
the CD8+ T cell population. (C) The change in the percentage of peripheral blood CD4+CD25+FoxP3+ T cells within the total CD4+ T cell population.. R
vs. NR=not significant.
doi:10.1371/journal.pone.0002711.g004
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study concerned the prediction of acute rejection following
reduction of immunosuppression by measuring CTLp frequencies
[13]. The authors found that low CTLp frequencies (,10/10*10
6
PBMC) identified patients in whom immunosuppression could be
safely reduced. The low CTLp frequencies observed by van
Besouw et al. might be viewed as a state of immune quiescence,
which in some way appeared to be reflected by a low memory T
cell: Treg ratio in our study. Combining the assessment of CTLp
frequencies and memory T cell: Treg ratios might provide a strong
monitoring tool.
Although the results of our study are based on a relatively small
sample size, similar studies with comparable or larger number of
patients have not been published. It is important that our findings
are reproduced in a second validation cohort of patients before
they can be used for the management of patients. We recognize
that in a number of the assays we used, overall reactivity rather
than donor reactivity was measured. In clinical practice however,
monitoring tools will especially be welcomed if they are easy and
fast to perform, give reproducible results, require small blood
volumes of the patient, and do not require donor material.
In conclusion, in this study we have monitored a variety of
phenotypic and functional T cell markers in the peripheral blood
of renal transplant patients in order to find a marker that would
help to predict the occurrence of acute rejection following the
discontinuation of tacrolimus. Flow cytometric T cell analysis was
found to be the most informative in our study and revealed an
association between the occurrence of rejection and 1) the ratio of
memory T cells and Treg immediately prior to the start of
tacrolimus reduction and 2) changes in the distribution of naive,
effector and memory T cells over time. These findings may
contribute to the development of in vitro monitoring tools to
identify transplant patients in whom immunosuppression can be
safely reduced in order to avoid long-term side effects.
Figure 5. Changes in the functional capacity of T cells isolated from the peripheral blood of transplant patients between the time of
transplantation (T0) and the start of tacrolimus withdrawal (T1). A positive value indicates an increase and a negative value indicates a
decrease of the value in time. A CFSE MLR in combination with Modfit LT
TM software was used to calculate the precursor frequency and the number
of mitotic events of allo- and 3
rd-party-reactive CD4+ and CD8+ T cells. (A) The change (y-axis) in the precursor frequency of alloreactive CD4+ and
CD8+ T cells. (B) The change in the number of mitotic events (ME) of CD4+ and CD8+ alloreactive T cells. (C) The functional capacity to suppress anti-
donor responses of Treg isolated before transplantation (T0, white circles) and before the start of tacrolimus reduction (T1, black circles) in 5 rejectors
(upper graphs) and 4 non-rejectors (lower graphs).
doi:10.1371/journal.pone.0002711.g005
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